FlexFactory [Cytiva]
Bionova Scientific, a CDMO, is entering the advanced therapy manufacturing space by installing its third FlexFactory manufacturing platform while maintaining their core monoclonal antibody (mAb) business. Bionova will also use Cytiva’s Fast Trak process development services to help advance their entry into genomic medicines.
“Using Cytiva’s end-to-end solutions, we’ll have an exceptional platform to support the manufacture of genomic medicines,” says Fabio Fonseca, PhD, senior director, pDNA process development, Bionova Scientific. “Together with our team and technology stack, we are well positioned to deliver plasmid DNA with speed, quality and patient safety.”
The FlexFactory platform for advanced therapies offers substantial benefits that reduce business risks, increase operational speed, faster product ramp-up, and enhance flexibility, according to Ludovic Brellier, president of hardware solutions, Cytiva. Its built-in compliance features and robust quality controls helps improve regulatory adherence and minimize production issues, he continues, while its modular setup allows rapid adaptation to market shifts.
Bionova’s facility in The Woodlands, TX celebrated its grand opening on May 29, with the new FlexFactory slated for delivery in Q3 2025. For more information on the FlexFactory manufacturing platform, click here.
